🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Avantor, Inc. AVTR R3KPHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.avantorsciences.com
Company Profile ↓
$15.25
+16.68% 1Y
Mkt Cap$10.31B
P/E-17.94
P/B1.79
52W High$15.60
52W Low$7.41
Book Value$8.32
EPS (TTM)$-0.85

Company Overview

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 23.0% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $6.55B (-3.4% YoY); net profit $-530.20M.
  • Trailing 12 Months Year-on-year growth — revenue +0.5%, earnings -37.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 23.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:23.04%
1 Year:0.50%

Compounded Profit Growth

5 Years:-
1 Year:-37.40%

Stock Price Performance

1 Year:+16.68%
6 Months:+87.12%
3 Months:+57.38%
1 Month:+12.21%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 96% of range
$7.41 $15.60
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)69.44 · Neutral
Price Performance
1M+12.21%
3M+57.38%
6M+87.12%
1Y+16.68%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 23.0% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-17.94
Industry PE
24.83
Forward P/E
17.30
PEG Ratio
-
Book Value
$8.32
Price to Book
1.79
P/S
1.53
EV/EBITDA
14.52
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
23.04%
Profit 5Y
-
Revenue (YoY)
0.50%
Earnings (YoY)
-37.40%

Profitability & Returns

ROCE
-2.36%
ROE
-9.70%
ROA
2.69%
Profit Margin
-8.81%
Op Margin
7.16%
Gross Margin
31.82%
EPS (Latest Qtr)
$0.06
EPS (TTM)
$-0.85

Balance Sheet & Liquidity

Debt/Equity
0.66
Quick Ratio
1.05
Current Ratio
1.78
Debt
$3.70B
Total Assets
$11.66B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.50%
Chg in Prom Hold
-0.00%
FII / Inst Holding
105.34%
Chg in FII Hold
-0.09%

Financial Snapshot

Enterprise Value
$10.31B
Total Revenue (TTM)
$6.56B
EBITDA
$943.70M
Free Cash Flow
$450.34M
Operating Cash Flow
$597.00M
Shares Outstanding
676.36M
Gross Margin
31.82%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AVTR Avantor, Inc. R3KPHARMA 15.25 -17.94 $10.31B 0.00% -2.36% -9.70% 23.04% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 1.42B1.48B1.49B1.47B1.48B1.53B1.50B1.52B1.52B1.48B1.60B1.79B1.79B1.86B1.83B1.95B1.91B1.86B1.78B1.74B1.72B1.68B1.70B1.71B--1.68B1.62B1.66B1.58B1.69B
Cost of Revenue --------------------------1.13B1.10B1.14B1.08B1.16B
Gross Profit 440.30M468.00M478.70M432.80M475.20M491.10M474.00M480.40M501.90M490.60M506.40M581.60M612.80M626.50M615.90M689.90M647.70M650.70M624.80M590.00M578.60M570.50M581.50M564.40M--554.10M526.50M523.90M500.70M537.00M
Operating Expenses --------------------------425.30M390.30M392.40M401.20M415.20M
Operating Income -94.40M132.20M-137.60M119.10M143.20M-158.40M166.60M177.20M-266.30M254.70M237.20M307.00M295.60M275.80M231.20M71.70M210.20M146.30M175.80M124.60M--128.80M136.20M131.50M99.50M121.80M
EBITDA --------------------------227.80M-540.80M224.10M203.40M226.20M
Interest Expense --------------------------43.40M44.20M40.00M42.90M39.40M
Pretax Income --------------------------81.70M-689.50M80.80M55.50M81.20M
Tax Provision --------------------------17.00M22.30M28.40M12.20M43.10M
Net Income --26.90M34.50M--6.20M-48.70M22.10M70.60M47.00M60.20M-42.20M51.60M164.00M157.80M156.80M190.40M187.40M167.00M121.50M-7.30M108.40M60.40M92.90M57.80M--64.70M-711.80M52.40M43.30M38.10M
Diluted EPS -0.79-0.70-0.26-0.94-0.59-0.980.010.090.050.08-0.100.060.250.240.240.280.280.250.18-0.010.160.090.140.08--0.09-1.040.080.060.06

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.25B5.86B6.04B6.39B7.39B7.51B6.97B6.78B6.55B
Gross Profit 432.80M1.82B1.92B2.08B2.50B2.60B2.36B2.28B2.14B
Operating Income -210.40M413.50M551.80M706.80M972.20M1.13B696.40M1.08B-246.20M
Net Income -112.70M-86.90M37.80M116.60M572.60M686.50M321.10M711.50M-530.20M
Diluted EPS --2.69-0.840.090.851.010.471.04-0.78

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --9.91B9.77B9.91B13.90B13.46B12.97B12.11B11.79B
Total Equity -510.60M-2.62B-3.05B2.46B2.67B4.20B4.86B5.25B5.96B5.57B
Cash & Equivalents --184.70M186.70M286.60M301.70M372.90M262.90M261.90M365.40M
Long Term Debt --6.78B5.02B4.87B6.98B5.92B5.28B3.23B3.92B
Total Liabilities --9.10B7.31B7.23B9.70B8.61B7.72B6.16B6.23B
Current Liabilities --1.10B1.07B1.24B1.45B1.66B1.48B2.01B1.38B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -167.50M200.50M354.00M929.80M953.60M843.60M870.00M840.80M623.80M
Investing Cash Flow -6.68B-23.20M-42.10M-59.10M-4.12B-109.60M-143.70M438.90M-130.50M
Financing Cash Flow 6.96B-170.30M-307.80M-782.90M3.22B-648.70M-843.70M-1.28B-409.40M
Capital Expenditure -25.20M-37.70M-51.60M-61.60M-111.10M-133.40M-146.40M-148.80M-128.80M
Free Cash Flow -192.70M162.80M302.40M868.20M842.50M710.20M723.60M692.00M495.00M
Share Buybacks ------0075.10M

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 34.7%31.0%31.8%32.5%33.9%34.6%33.9%33.6%32.7%
Operating Margin % -16.9%7.1%9.1%11.1%13.2%15.0%10.0%16.0%-3.8%
Net Margin % -9.0%-1.5%0.6%1.8%7.8%9.1%4.6%10.5%-8.1%
ROE % 4.3%2.8%1.5%4.4%13.6%14.1%6.1%11.9%-9.5%
ROCE % -4.7%6.3%8.2%7.8%9.6%6.1%10.7%-2.4%

Shareholding Pattern

Insiders
1.50%
Institutions
105.34%
Public Float
106.94%

Top Institutional Holders

#Holder% HeldSharesValue
1 Dodge & Cox Inc. 17.75% 120.02M $1.86B
2 Blackrock Inc. 10.39% 70.28M $1.09B
3 Vanguard Portfolio Management LLC 4.63% 31.34M $486.45M
4 Vanguard Capital Management LLC 4.55% 30.80M $478.06M
5 Greenhaven Associates, Inc. 3.64% 24.64M $382.37M
6 State Street Corporation 3.19% 21.57M $334.81M
7 Dimensional Fund Advisors LP 3.02% 20.41M $316.80M
8 Engine Capital Management, LP 2.94% 19.86M $308.24M
9 Barrow, Hanley Mewhinney & Strauss, LLC 2.92% 19.74M $306.30M
10 New Mountain Capital, L.L.C. 2.07% 14.00M $217.28M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AVTR

Google News Fri, 04 Sep 2026

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQblNOQUpsTjJpb2hZdDRRWnY4ZF9qTy05bGZNMVZlWnlxMGYxc1lmNjAxUEc0SU1LVFNiUHlfeDVNbUtNcnV4TFA5c2dvT215SFhxNzJNQnBLR2pXdDNqUWpiRTJLSlM3UlcxRU9WRDdrNWFRNTRCOVpyTkQ3YWF6b09sNkxmd1lXY2kxNH…

Google News Mon, 07 Sep 2026

Avantor, Inc. (AVTR) Stock Analysis: Navigating the Healthcare Landscape with a Forward P/E of 16.98 - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNel9JamhIdGpBNXIySElSQjR5d1Iza3JoczRQaTZnMjdmS2thOHVyc2Nwc0tVOU9ENm0yNm82QVU4VDZpVk96aXlUNFVVRDBqdVlDUUpnUTZqbWtiejJtTTZqSm9YZThPMkxXOTVIcW9lbm9LWWVST3ZXOEt6cktxS2hVdUpWU0VsX2JFdn…

Google News Sun, 06 Sep 2026

Does Avantor’s (AVTR) EVP Transition Undermine or Validate Its Improving Earnings Narrative? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOU201endnZDMtSVBtTW9QVHdpQ3Jsc1lIbzNEenhFaDJGaWdEWFVZVExvTktHLVNWN2NFWXlxU2xZRnZzS09hZkZ2UmNYdENvaDZaOHphMU1zSlc2Z2dNVUljRkVLZGQySWprelRMTWRjdGNucHdtZy1FZjZxWExTMkZtNVlHQ0ktS1A1aE…

Google News Wed, 02 Sep 2026

Is It Too Late to Buy Avantor Inc (AVTR) After 3.2% Rally? GF Va - gurufocus.com

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQQk1lTnNjSlNzd1pUNHBndnRFMURpb09ITXdoUWRIT09jUEp2d2NlZUpiUG1JeEN0dVRpUmR1c0NOUWVBZTFyRVVLR21zN0UzN01Sa2VnZm1oY213WlBoLVp3cWszOXNJNy01MHV3dGx2MXExbUdnUEp1R0xrMlBPeTN1NFhkcVNuUktCOU…

Google News hu, 30 Jul 2026

Avantor Stock Surged Because One Segment Stopped Shrinking - Trefis

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPVDFFNTZUTDJGWVpsRnEtekNVZEdLbDhadGhldFhVLTlwYWs2R0U4VWpxYlNHczdGa0xMQjFFMmNDdURzWDRmYzlWejRLYXRqcGVfVUZsbmhsdjdTQ09TUTF3MUJ6UEdKa2tsTS1sVHFJUjMxUS1EclpEbUFhSEJkdExaUTFhQ0V3eXhBbz…

Google News Mon, 08 Jun 2026

Avantor (AVTR) Stock Grinds Higher As Turnaround Story Builds - StocksToTrade

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE5CbGxOZDFYRUVYT2NxR3hYUGpuOEpCZEE0M1FxcmVfSW5haDhLT2c2Wk9leXlZZTdnWGN4Rkc5V3BGTmhjak9IR3BMMVlQQnhmUVRUUkt4d3JzYzR6ZDY0NWlEZVBlWEJIRGpIdjFKVnBuQQ?oc=5" target="_blank">Avantor (AVTR…

AVTR — Frequently Asked Questions

What is the current share price of Avantor, Inc. (AVTR)?

As of 2026-09-19 21:16 PDT, Avantor, Inc. (AVTR) trades at $15.25 on NYSE. Its 52-week range is $7.41 to $15.60.

What is the market capitalisation of AVTR?

Avantor, Inc. (AVTR) has a market capitalisation of $10.31B on NYSE.

What is the P/E ratio of AVTR?

AVTR trades at a trailing price-to-earnings (P/E) ratio of -17.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.79.

What is the return on equity (ROE) of AVTR?

AVTR has a return on equity (ROE) of -9.70%. Its return on capital employed (ROCE) is -2.36%.

Is AVTR a good stock to buy?

This page provides a data-driven analysis of Avantor, Inc. (AVTR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space